HRT Financial’s Akari Therapeutics AKTX Stock Holding History

HRT Financial’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$140K	Buy	+13,745	New	+$119K	﹤0.01%	3519
2021 Q4	–	Sell	-24	Closed	-$31K	–	3105
2021 Q3	$31K	Sell	24 -3	-11%	-$4.08K	﹤0.01%	3105
2021 Q2	$37K	Buy	27 +7	+35%	+$11.2K	﹤0.01%	2697
2021 Q1	$42K	Buy	+20	New	+$45.3K	﹤0.01%	2557
2020 Q4	–	Sell	-63	Closed	-$88K	–	1795
2020 Q3	$88K	Buy	63 +48	+320%	+$71.2K	﹤0.01%	1562
2020 Q2	$26K	Buy	+15	New	+$22.9K	﹤0.01%	1380

Other funds holding AKTX

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

Truvestments Capital Sarasota, Florida $673M AUM 55.24% 1-Year Est. Return

HRT Financial's AKTX Position: Q2 2026 in Review

HRT Financial opened a new position in Akari Therapeutics (AKTX) in Q2 2026: 13,745 shares worth $140K. The stake represents ﹤0.01% of the portfolio and ranks #3519 among its holdings. This is a return to the name: HRT Financial previously reported a position in AKTX as recently as Q3 2021.

HRT Financial first reported a position in AKTX in Q2 2020 and has held it in 6 quarters since. 9 funds tracked by Wall St. Rank hold AKTX as of Q2 2026.

HRT Financial held 13,745 shares of Akari Therapeutics worth $140K as of Q2 2026.
Akari Therapeutics was a new HRT Financial position in Q2 2026.
Akari Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3519 holding.
HRT Financial first reported a position in Akari Therapeutics in Q2 2020 and has held it in 6 quarters since.
9 funds tracked by Wall St. Rank held Akari Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.